Download
protocol
70kb

pdf?

Abstract for RNasin^® Ribonuclease Inhibitor

RNasin^® Ribonuclease Inhibitor has broad-spectrum RNase inhibitory properties. The 50kDa protein exerts its inhibitory effect by noncovalently binding to RNases at a 1:1 ratio. The K_i value for the binding of RNasin^® Ribonuclease Inhibitor to RNase (e.g., RNase A) is approximately 10^–14M. Promega offers two different preparations: Natural RNasin^® Ribonuclease Inhibitor (Cat.# N2111, N2115) and Recombinant RNasin^® Ribonuclease Inhibitor (Cat.# N2511, N2515). These products are purified using a combination of ion exchange and affinity chromatography, and Natural and Recombinant RNasin^® Ribonuclease Inhibitors are devoid of DNA exonuclease and endonuclease activity and RNase activity. In addition to its ability to inhibit RNase activity, RNasin^® Ribonuclease Inhibitor has been shown to inhibit angiogenesis induced by angiogenin, basic fibroblast growth factor (bFGF) and sodium orthovanadate. Moreover, RNasin^® Ribonuclease Inhibitor reduced neovascularization evoked by implanted tumor cells and significantly inhibited tumor growth in a murine model.

Natural RNasin^® Ribonuclease Inhibitor is isolated from human placenta. Preparations may contain multiple polymorphic inhibitors that differ slightly in amino acid sequence. The N-terminus is blocked.

Protocols
Index

Part# 9PIN211
Printed in USA. Revised 4/08.
Instructions for Use of Products N2111 & N2115: Request this protocol.

Printed publications disclaimer.